tetano
Editor, Senior Moderator
Expert Rev Proteomics
. 2023 Mar 15.
doi: 10.1080/14789450.2023.2191845. Online ahead of print.
LC-MS/MS: A sensitive and selective analytical technique to detect COVID-19 protein biomarkers in the early disease stage
Siva Nageswara Rao Gajula[SUP] 1 [/SUP], Ankita Sahebrao Khairnar[SUP] 1 [/SUP], Pallavi Jock[SUP] 1 [/SUP], Nikita Kumari[SUP] 1 [/SUP], Kendre Pratima[SUP] 1 [/SUP], Vijay Munjal[SUP] 1 [/SUP], Pavan Kalan[SUP] 1 [/SUP], Rajesh Sonti[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: The COVID-19 outbreak has put enormous pressure on the scientific community to detect infection rapidly, identify the status of disease severity, and provide an immediate vaccine/drug for the treatment. Relying on immunoassay and a real-time reverse transcription polymerase chain reaction (rRT-PCR) led to many false-negative and false-positive reports. Therefore, detecting biomarkers is an alternative and reliable approach for determining the infection, its severity, and disease progression. Recent advances in liquid chromatography and mass spectrometry (LC-MS/MS) enable the protein biomarkers even at low concentrations, thus facilitating clinicians to monitor the treatment in hospitals.
Areas covered: This review highlights the role of LC-MS/MS in identifying protein biomarkers and discusses the clinically significant protein biomarkers such as Serum amyloid A, Interleukin-6, C-Reactive Protein, Lactate dehydrogenase, D-dimer, cardiac troponin, ferritin, Alanine transaminase, Aspartate transaminase, gelsolin and galectin-3-binding protein in COVID-19, and their analysis by LC-MS/MS in the early stage.
Expert opinion: Clinical doctors monitor significant biomarkers to understand, stratify, and treat patients according to disease severity. Knowledge of clinically significant COVID-19 protein biomarkers is critical not only for COVID-19 caused by the coronavirus but also to prepare us for future pandemics of other diseases in detecting by LC-MS/MS at the early stages.
Keywords: Biomarkers; COVID-19; LC-MS/MS; Proteomics; SARS-CoV-2.
. 2023 Mar 15.
doi: 10.1080/14789450.2023.2191845. Online ahead of print.
LC-MS/MS: A sensitive and selective analytical technique to detect COVID-19 protein biomarkers in the early disease stage
Siva Nageswara Rao Gajula[SUP] 1 [/SUP], Ankita Sahebrao Khairnar[SUP] 1 [/SUP], Pallavi Jock[SUP] 1 [/SUP], Nikita Kumari[SUP] 1 [/SUP], Kendre Pratima[SUP] 1 [/SUP], Vijay Munjal[SUP] 1 [/SUP], Pavan Kalan[SUP] 1 [/SUP], Rajesh Sonti[SUP] 1 [/SUP]
Affiliations
- PMID: 36919634
- DOI: 10.1080/14789450.2023.2191845
Abstract
Introduction: The COVID-19 outbreak has put enormous pressure on the scientific community to detect infection rapidly, identify the status of disease severity, and provide an immediate vaccine/drug for the treatment. Relying on immunoassay and a real-time reverse transcription polymerase chain reaction (rRT-PCR) led to many false-negative and false-positive reports. Therefore, detecting biomarkers is an alternative and reliable approach for determining the infection, its severity, and disease progression. Recent advances in liquid chromatography and mass spectrometry (LC-MS/MS) enable the protein biomarkers even at low concentrations, thus facilitating clinicians to monitor the treatment in hospitals.
Areas covered: This review highlights the role of LC-MS/MS in identifying protein biomarkers and discusses the clinically significant protein biomarkers such as Serum amyloid A, Interleukin-6, C-Reactive Protein, Lactate dehydrogenase, D-dimer, cardiac troponin, ferritin, Alanine transaminase, Aspartate transaminase, gelsolin and galectin-3-binding protein in COVID-19, and their analysis by LC-MS/MS in the early stage.
Expert opinion: Clinical doctors monitor significant biomarkers to understand, stratify, and treat patients according to disease severity. Knowledge of clinically significant COVID-19 protein biomarkers is critical not only for COVID-19 caused by the coronavirus but also to prepare us for future pandemics of other diseases in detecting by LC-MS/MS at the early stages.
Keywords: Biomarkers; COVID-19; LC-MS/MS; Proteomics; SARS-CoV-2.